MICE ORTHOTOPIC IMPLANTATION FOR HUMAN TUMORS

Desarrollado por: Instituto de Investigación Biomédica de Bellvitge (IDIBELL)

Descripción

UNMET NEED:

Replicating tumor microenvironment is a main challenge in cancer drug development

PROPOSED SOLUTION:

In-house orthotropic mice tumor models for new cancer drug development (Orthoxenograft®)

FEATURES:

  • Personalized oncologic mice models for preclinical studies (Orthoxenograft®)
  • In-House tumor bank (OrthoXenoBank®) for orthotropic mice tumor models

Aplicaciones

XENOPAT offers to main type of applications:

  • Advanced Preclinical services: XENOPAT offers researchers and pharmacological companies the possibility to generate orthoxenografts® and also to use the OrthoXenoBank®. Using these models, oncologic drug development acquires a new and powerful tool to guide its success through the development pipeline.

  • Personalized Oncologic Treatment sevices: XENOPAT offers healthcare professionals and oncologic patients the most advanced technology in order to select the best treatment in the fight against cancer. XENOPAT aims to be a key decision tool in the oncologic personalized treatments.

Estado de protección

The technology has been under development for the last 10 years and thus the technology is fully established. Several proofs of concept of its use have been published in high impact peer reviewed journals.

Responsable: Área de Desarrollo de Negocio e Innovación // Oficina de Transferencia de Tecnología

Contacto (Tel./mail): 93 260 71 06 / Innovacio@idibell.cat

Estado:
N/A
Tecnología sanitaria:
N/A